Despite the lack of RCTs on tofogliflozin with atherosclerotic cardiovascular disease or heart failure as primary outcomes and, thus, the lack of sufficient evidence, it is likely that tofogliflozin, like other SGLT2 inhibitors, has a beneficial effect on cardiovascular disease, particularly on cardiac function and heart failure. This evidence concerns the gene SLC5A2 and cardiovascular disorder.